Galvusmet

# Galvusmet ## Overview - **Classification**: Oral Antidiabetic (DPP-4 Inhibitor + Biguanide combination) - **Mechanism**: Vildagliptin inhibits DPP-4, increasing incretin hormones, enhancing insulin release and suppressing glucagon. Metformin reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity. ## Primary Indications 1. **Type 2 Diabetes Mellitus** - As an adjunct to diet and exercise in adults. 2. **Combination Therapy** - When vildagliptin and metformin are appropriate, or when either monotherapy or metformin with another oral antidiabetic agent does not achieve adequate glycemic control. ## Adult Dosing ### Standard Dosing **Type 2 Diabetes Mellitus** - **Dose**: **50 mg vildagliptin / 500 mg metformin**, **50 mg / 850 mg**, or **50 mg / 1000 mg**. - **Frequency**: Twice daily (BID) - **Route**: Oral - **Maximum Dose (daily)**: **100 mg vildagliptin** and **2000 mg metformin** - **Special Considerations**: Take with or immediately after meals to reduce GI side effects of metformin. ### Dose Adjustments - **Renal Impairment**: - **CrCl ≥ 60 mL/min**: No dose adjustment needed. - **CrCl 30-59 mL/min**: Max **50 mg vildagliptin / 1000 mg metformin** daily (e.g., **50 mg/500 mg** BID or **1000 mg** once daily). Metformin initiation not recommended if CrCl < 45 mL/min. - **CrCl < 30 mL/min**: **Contraindicated**. - **Hepatic Impairment**: **Contraindicated** for metformin component. Vildagliptin not recommended for moderate to severe impairment. - **Elderly Patients**: Monitor renal function more frequently due to potential age-related decline. ## Pediatric Dosing Galvusmet is **not indicated** for use in children and adolescents. Safety and efficacy have not been established in patients under 18 years of age. ### Neonates (0-28 days) - **Not indicated**. ### Infants (1-12 months) - **Not indicated**. ### Children (1-12 years) - **Not indicated**. ### Adolescents (13-18 years) - **Not indicated**. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to vildagliptin or metformin. - **Absolute**: Renal impairment (eGFR < 30 mL/min/1.73m²). - **Absolute**: Acute or chronic metabolic acidosis, including diabetic ketoacidosis (DKA). - **Absolute**: Acute heart failure, unstable angina, or recent myocardial infarction. - **Absolute**: Hepatic impairment. - **Absolute**: Acute or chronic disease with tissue hypoxia (e.g., respiratory failure, shock). - **Absolute**: Alcohol intoxication or alcoholism. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, vomiting, diarrhea, abdominal pain, loss of appetite (metformin-related). - **Common (1-10%)**: Headache, dizziness, tremor, asthenia, nasopharyngitis, arthralgia. - **Serious but Rare**: Pancreatitis, Lactic Acidosis (metformin), Hepatotoxicity, Angioedema, Bullous Pemphigoid. ### Key Drug Interactions - **Iodinated Contrast Media**: Hold metformin **before and 48 hours after** procedures involving contrast. Risk of lactic acidosis. - **Cationic Drugs (e.g., Cimetidine, Furosemide, Nifedipine)**: May increase metformin concentration. Monitor for metformin toxicity. - **Carbonic Anhydrase Inhibitors (e.g., Topiramate)**: Increased risk of lactic acidosis. - **Alcohol**: Potentiates metformin's effect on lactate metabolism, increasing lactic acidosis risk. Avoid excessive intake. ## Monitoring & Follow-up - **Before Treatment**: - Renal function (eGFR). - HbA1c. - Liver function tests (ALT, AST). - **During Treatment**: - Renal function: At least **annually** if eGFR ≥ 60 mL/min; **2-4 times a year** if eGFR 30-59 mL/min. - HbA1c: **Every 3-6 months**. - Vitamin B12 levels: **Annually** in patients with risk factors for deficiency or on prolonged metformin therapy. - Clinical Signs: Monitor for pancreatitis, hepatotoxicity, and symptoms of lactic acidosis. - **Clinical Signs**: Watch for unexplained muscle pain, malaise, respiratory distress, increased somnolence (possible lactic acidosis). ## Clinical Pearls - 💡 **Timing**: Always take Galvusmet **with or immediately after meals** to minimize GI side effects of metformin. - 💡 **Lactic Acidosis Risk**: Counsel patients on the symptoms of lactic acidosis and to seek immediate medical attention if they occur. Inform them about situations increasing risk (e.g., severe illness, dehydration, alcohol). - 💡 **Renal Function**: Emphasize the importance of regular renal function monitoring, especially in elderly patients or those with risk factors for kidney disease. - 💡 **Missed Dose**: If a dose is missed, take the next dose at the regular scheduled time. Do not double the dose. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.